Eli Lilly and Resilience Boost Manufacturing for Diabetes and Weight-Loss Drugs
Eli Lilly is putting $750 million toward expanding its manufacturing network for drug delivery devices. As part of the…
-
-
What You Need to Know About Buying Weight Loss Drugs Online
Researchers at a major university recently took a close look at how online companies sell popular weight loss drugs….
-
Weight Loss Drugs Work, But High Costs Keep Them Out of Reach for Many Latinos
Nearly 25% of Latino adults in the U.S. live with obesity. While breakthrough medications like GLP-1s have changed the…
-
Novo Nordisk Price Target Rises to $80 as Oral Wegovy Surpasses 3 Million Prescriptions
Novo Nordisk received an upgraded price target of $80, while market analysts assigned the stock a Modest Buy rating….
-
Medicare is Finally Covering Weight-Loss Drugs: What You Need to Know
About one in eight adults now takes a GLP-1 drug to help lose weight. For years, though, Medicare users…
-
First Weight-Loss Pill Gets the Green Light
For years, the most effective weight-loss drugs came with a catch: you had to inject them. That’s changing. Regulators…
-
Viking Therapeutics: Is This GLP-1 Contender Worth Watching?
The GLP-1 drug class has become one of the hottest areas in pharma right now. Viking Therapeutics is one…
-
Zepbound and Reproductive Health: What to Know About Pregnancy, Breastfeeding, and Birth Control
Tirzepatide, sold under the brand name Zepbound, is a weight-loss drug that works on two gut hormones at once…
-
Novo Nordisk Takes an Early Lead in the Weight Loss Pill Race
Novo Nordisk got greenlit by the Food and Drug Administration for its daily semaglutide pill in December 2025. This…
-
Clinical Trial Evaluates Oral Orforglipron Against Semaglutide
A new once-daily tablet, orforglipron, outperformed oral semaglutide in a phase 3 clinical trial. Researchers evaluated this new receptor…
